|
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
1.000 |
Biomarker
|
disease |
BEFREE |
The limited DNA-excision repair in UV-irradiated nondividing fibroblasts from xeroderma pigmentosum complementation group C (XP-C) occurs in localized chromatin regions generating large DNA segments (at least 30-70 kb) free of pyrimidine dimers.
|
2342504 |
1990 |
|
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
We show that drug-induced resistance is a result of p53-dependent upregulation of the nucleotide excision repair (NER) genes xeroderma pigmentosum complementation group C (XPC) and damaged DNA-binding protein 2 (DDB2), which stimulate the repair of DNA interstrand cross-links (ICLs) arising from O(6)-chloroethylguanine.
|
23604128 |
2014 |
|
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
1.000 |
Biomarker
|
disease |
BEFREE |
Primary xeroderma pigmentosum complementation group C (XP-C) cells, whether proliferating or nondividing, removed no CPD from either rDNA strand in 24 h post-UV, a result which supports earlier conclusions that XP-C cells lack the general, transcription-independent pathway of nucleotide excision repair.
|
7512688 |
1994 |
|
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
The mean XPC mRNA levels in the cell lines from the XP-C probands were 24% (P<10(-7)) of that in 10 normal controls.
|
16081512 |
2006 |
|
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
1.000 |
Biomarker
|
disease |
BEFREE |
Xeroderma pigmentosum, complementation group C (XPC) is an accessory recognition gene involved in the nucleotide excision repair (NER) pathway, which is activated during the initial DNA damage recognition stage.
|
30628719 |
2019 |
|
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
The present study has genotyped 334 subjects from North Indian population for xeroderma pigmentosum complementation Group C (XPC) rs2228001A>C, XPC rs77907221 polyadenylate (PAT) deletion/insertion (D/I), xeroderma pigmentosum complementation Group D - rs13181A>C, and xeroderma pigmentosum complementation Type G rs17655 G>C polymorphisms with polymerase chain reaction (PCR)-restriction-fragment length polymorphism or allele-specific PCR methods.
|
29893334 |
2018 |
|
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
To investigate the association between two Xeroderma pigmentosum group C polymorphism (XPC Lys939Gln and insertion/deletion PAT -/+ in intron 9) and bladder cancer (BC) susceptibility.
|
19924443 |
2010 |
|
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Loss or mutation of XPC may be an early event during skin carcinogenesis that provides a selective advantage for initiation and progression of squamous cell carcinomas in non XP-C patients.
|
20616346 |
2010 |
|
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
1.000 |
Biomarker
|
disease |
BEFREE |
Attenuated expression of the DNA damage response protein Xeroderma Pigmentosum complementation group C (XPC) has been described in bladder cancer.
|
25927440 |
2015 |
|
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
AFB1 DNA adduct levels, XPC genotypes, and XPC protein levels were tested with a comparative enzyme-linked immunosorbent assay, TaqMan polymerase chain reaction for XPC genotypes, and immunohistochemistry, respectively.
|
20658464 |
2010 |
|
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
1.000 |
Biomarker
|
disease |
BEFREE |
Recessive dystrophic epidermolysis bullosa (RDEB), Kindler syndrome (KS) and xeroderma pigmentosum complementation group C (XPC) are three genodermatoses with high predisposition to cancer development.
|
30693469 |
2019 |
|
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
1.000 |
Biomarker
|
disease |
BEFREE |
Xeroderma pigmentosum complementation group C (XPC) is responsible for DNA damage recognition in the initial steps of the nucleotide excision repair pathway.
|
17052994 |
2007 |
|
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Objectives In the present study, we examined available articles from online databases to comprehensively investigate the effect of the XPC (xeroderma pigmentosum complementation group C) rs2228000 polymorphism on the risk of different types of clinical cancer.
|
31710080 |
2019 |
|
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
1.000 |
Biomarker
|
disease |
BEFREE |
In A549 cells, cisplatin exposure led to a significantly higher expression of genes coding for proteins mediating G2/M arrest and apoptosis (mouse double minute 2 homolog (MDM2), xeroderma pigmentosum complementation group C (XPC), stress inducible protein (SIP) and p21) compared to resistant cells.
|
28746345 |
2017 |
|
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
1.000 |
Biomarker
|
disease |
BEFREE |
Xeroderma pigmentosum complementation group C (XPC) is one of the essential damage recognition proteins of the GG-NER pathway and its dysfunction results in xeroderma pigmentosum (XP), a disorder involving photosensitivity and a predisposition to cancer.
|
24366067 |
2013 |
|
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
1.000 |
Biomarker
|
disease |
BEFREE |
The xeroderma pigmentosum complementation group C (XPC) is responsible for removal of bulky helix-distorting DNA lesions.
|
21104992 |
2011 |
|
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
1.000 |
Biomarker
|
disease |
BEFREE |
We have measured the removal of UV-induced pyrimidine dimers from DNA fragments of the adenosine deaminase (ADA) and dihydrofolate reductase (DHFR) genes in primary normal human and xeroderma pigmentosum complementation group C (XP-C) cells.
|
1649389 |
1991 |
|
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
We investigated the association of urinary bladder cancer with genetic polymorphisms in the xeroderma pigmentosum complementation group C (XPC), group D (XPD) and group G (XPG), X-ray repair cross-complementing group 1 (XRCC1) and group 3 (XRCC3), Nijmegen breakage syndrome 1 (NBS1), cyclin D1, methylene-tetrahydrofolate reductase (MTHFR), NAD(P)H dehydrogenase quinone 1 (NQO1), H-ras and glutathione S-transferase theta 1 (GSTT1) genes.
|
14688016 |
2004 |
|
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
1.000 |
Biomarker
|
disease |
BEFREE |
We have isolated a mouse homologue of the human gene for XP group C and generated XPC-deficient mice by using embryonic stem cell technology.
|
7675084 |
1995 |
|
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
1.000 |
Biomarker
|
disease |
BEFREE |
Significant homology of the C-terminal 346 amino acids with both the human XPC and Saccharomyces cerevisiae Rad4 protein sequences is observed, suggesting that these proteins are functional homologs.
|
8127661 |
1994 |
|
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
1.000 |
Biomarker
|
disease |
BEFREE |
The current study aims to test the hypothesis that eIF3a may affect the drug response and prognosis of ovarian cancer patients receiving platinum-based chemotherapy by regulating xeroderma pigmentosum complementation group C (XPC) and p27(Kip1).
|
26213845 |
2015 |
|
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
These results extend our previous observations and indicate that defects in XPCC cause Xeroderma pigmentosum group C.
|
8298653 |
1993 |
|
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
1.000 |
Biomarker
|
disease |
BEFREE |
For example, the damaged DNA-binding protein Radiation sensitive 4 (Rad4) in <i>Saccharomyces cerevisiae</i> is homologous to the mammalian NER protein Xeroderma Pigmentosum complementation group C (XPC).
|
29283431 |
2017 |
|
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
1.000 |
Biomarker
|
disease |
BEFREE |
A simian virus 40 (SV40) DNA fragment, encompassing the whole early region but having a defective origin of DNA replication, was previously used to transform human fibroblast cells derived from a patient suffering from xeroderma pigmentosum complementation group C (XP-C).
|
2547510 |
1989 |
|
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Patients with EADC demonstrated a significantly higher frequency of the XPC PAT homozygous variant genotype compared with asymptomatic controls (OR = 3.82; 95% CI = 1.05-13.93).
|
15878910 |
2005 |